医薬品受託製造開発機関(CDMO)アウトソーシングの世界市場予測・分析2019-2023

【英語タイトル】Contract Development and Manufacturing Organization (CDMO) Outsourcing Market by Product and Geography - Global Forecast and Analysis 2019-2023

Technavioが出版した調査資料(IRTNTR32014)・商品コード:IRTNTR32014
・発行会社(調査会社):Technavio
・発行日:2019年9月28日
・ページ数:136
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:消費財
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
Technavio社の本調査レポートでは、医薬品受託製造開発機関(CDMO)アウトソーシングの世界市場について調べ、医薬品受託製造開発機関(CDMO)アウトソーシングの市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、医薬品受託製造開発機関(CDMO)アウトソーシングの市場規模をセグメンテーション別(製品別(小分子、生物製剤)、)と地域別(グローバル)に分けて算出しました。Technavio社は医薬品受託製造開発機関(CDMO)アウトソーシングの世界市場規模が2019-2023期間中に年平均8%成長すると予測しています。
・サマリー
・レポートの範囲
・医薬品受託製造開発機関(CDMO)アウトソーシングの市場状況
・医薬品受託製造開発機関(CDMO)アウトソーシングの市場規模
・医薬品受託製造開発機関(CDMO)アウトソーシングの市場予測
・医薬品受託製造開発機関(CDMO)アウトソーシングの世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(小分子、生物製剤)
・医薬品受託製造開発機関(CDMO)アウトソーシングの顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market: About this market

Contract development and manufacturing organizations (CDMO) serve companies in the pharmaceutical industry on a contract basis. Technavio’s CDMO outsourcing market analysis considers sales from small molecules and biologics products. Our analysis also considers the sales of CDMO outsourcing products in APAC, Europe, North America, South America, and MEA. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing focus of vendors on expanding their presence will play a significant role in the small molecules segment to maintain its market position. Also, our global CDMO market report looks at factors such as the growing pharmaceutical industry, increasing demand for one-stop-shop CDMOs, and support of CDMOs in reducing the operational and capital expenses. However, the threat of infringement of intellectual property (IP) rights, serialization issue faced by CDMOs due to multiple production lines and need to comply with regulations may hamper the growth of the CDMO outsourcing industry over the forecast period.

Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market: Overview

Increasing demand for one-stop-shop CDMOs

One-stop-shop CDMOs have high expertise in gaining a competitive edge in the market. They consider various parameters including country-specific requirements, cost efficiency, patient friendliness, and product safety to offer customization of packaging. This enables pharma and biotech firms to safely launch their products in the market. CDMOs not only preserves scarce APIs but also monitors the entire value chain of a product. Such benefits of CDMOs will lead to the expansion of the global contract development and manufacturing organization (CDMO) outsourcing market at a CAGR of almost 8% during the forecast period.

Increasing market consolidation

M&As among CDMOs helps in the expansion of the customer base in new regions and improve the market reach. This inorganic strategy also aids in acquiring technological expertise and develop new innovative products to achieve differentiation from competitors. These developments are increasing consolidation in the market, which is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global contract development and manufacturing organization (CDMO) outsourcing market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global CDMO outsourcing market is highly fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading CDMO outsourcing manufacturers, that include Aenova Holding GmbH, Almac Group Ltd., Catalent Inc., FAMAR Health Care Services, FAREVA SA, Lonza Group Ltd., Recipharm AB, Siegfried Holding AG, The Lubrizol Corp., and Thermo Fisher Scientific Inc.

Also, the CDMO outsourcing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Small molecules – Market size and forecast 2018-2023

Biologics – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

APAC – Market size and forecast 2018-2023

South America – Market size and forecast 2018-2023

MEA – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Growing use of analytics by CDMOs

Growing demand for CDMOs for cell and gene therapies

Increasing market consolidation

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Aenova Holding GmbH

Almac Group Ltd.

Catalent Inc.

FAMAR Health Care Services

FAREVA SA

Lonza Group Ltd.

Recipharm AB

Siegfried Holding AG

The Lubrizol Corp.

Thermo Fisher Scientific Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Vendors: Key product offerings

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Small molecules – Market size and forecast 2018-2023 ($ billions)

Exhibit 21: Small molecules – Year-over-year growth 2019-2023 (%)

Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ billions)

Exhibit 23: Biologics – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by product

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ billions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Europe – Market size and forecast 2018-2023 ($ billions)

Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 32: APAC – Market size and forecast 2018-2023 ($ billions)

Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)

Exhibit 34: South America – Market size and forecast 2018-2023 ($ billions)

Exhibit 35: South America – Year-over-year growth 2019-2023 (%)

Exhibit 36: MEA – Market size and forecast 2018-2023 ($ billions)

Exhibit 37: MEA – Year-over-year growth 2019-2023 (%)

Exhibit 38: Key leading countries

Exhibit 39: Market opportunity

Exhibit 40: Impact of drivers and challenges

Exhibit 41: Vendor landscape

Exhibit 42: Landscape disruption

Exhibit 43: Vendors covered

Exhibit 44: Vendor classification

Exhibit 45: Market positioning of vendors

Exhibit 46: Aenova Holding GmbH – Vendor overview

Exhibit 47: Aenova Holding GmbH – Service segments

Exhibit 48: Aenova Holding GmbH – Organizational developments

Exhibit 49: Aenova Holding GmbH – Key offerings

Exhibit 50: Almac Group Ltd. – Vendor overview

Exhibit 51: Almac Group Ltd. – Product segments

Exhibit 52: Almac Group Ltd. – Organizational developments

Exhibit 53: Almac Group Ltd. – Key offerings

Exhibit 54: Catalent Inc. – Vendor overview

Exhibit 55: Catalent Inc. – Business segments

Exhibit 56: Catalent Inc. – Organizational developments

Exhibit 57: Catalent Inc. – Geographic focus

Exhibit 58: Catalent Inc. – Segment focus

Exhibit 59: Catalent Inc. – Key offerings

Exhibit 60: FAMAR Health Care Services – Vendor overview

Exhibit 61: FAMAR Health Care Services – Service segments

Exhibit 62: FAMAR Health Care Services – Organizational developments

Exhibit 63: FAMAR Health Care Services – Key offerings

Exhibit 64: FAREVA SA – Vendor overview

Exhibit 65: FAREVA SA – Business segments

Exhibit 66: FAREVA SA – Organizational developments

Exhibit 67: FAREVA SA – Key offerings

Exhibit 68: Lonza Group Ltd. – Vendor overview

Exhibit 69: Lonza Group Ltd. – Business segments

Exhibit 70: Lonza Group Ltd. – Organizational developments

Exhibit 71: Lonza Group Ltd. – Geographic focus

Exhibit 72: Lonza Group Ltd. – Segment focus

Exhibit 73: Lonza Group Ltd. – Key offerings

Exhibit 74: Recipharm AB – Vendor overview

Exhibit 75: Recipharm AB – Business segments

Exhibit 76: Recipharm AB – Organizational developments

Exhibit 77: Recipharm AB – Geographic focus

Exhibit 78: Recipharm AB – Segment focus

Exhibit 79: Recipharm AB – Key offerings

Exhibit 80: Siegfried Holding AG – Vendor overview

Exhibit 81: Siegfried Holding AG – Product segments

Exhibit 82: Siegfried Holding AG – Organizational developments

Exhibit 83: Siegfried Holding AG – Segment focus

Exhibit 84: Siegfried Holding AG – Key offerings

Exhibit 85: The Lubrizol Corp. – Vendor overview

Exhibit 86: The Lubrizol Corp. – Business segments

Exhibit 87: The Lubrizol Corp. – Organizational developments

Exhibit 88: The Lubrizol Corp. – Key offerings

Exhibit 89: Thermo Fisher Scientific Inc. – Vendor overview

Exhibit 90: Thermo Fisher Scientific Inc. – Business segments

Exhibit 91: Thermo Fisher Scientific Inc. – Organizational developments

Exhibit 92: Thermo Fisher Scientific Inc. – Geographic focus

Exhibit 93: Thermo Fisher Scientific Inc. – Segment focus

Exhibit 94: Thermo Fisher Scientific Inc. – Key offerings

Exhibit 95: Validation techniques employed for market sizing

Exhibit 96: Definition of market positioning of vendors



【掲載企業】

Aenova Holding GmbH, Almac Group Ltd., Catalent Inc., FAMAR Health Care Services, FAREVA SA, Lonza Group Ltd., Recipharm AB, Siegfried Holding AG, The Lubrizol Corp., and Thermo Fisher Scientific Inc.

★調査レポート[医薬品受託製造開発機関(CDMO)アウトソーシングの世界市場予測・分析2019-2023] (コード:IRTNTR32014)販売に関する免責事項を必ずご確認ください。
★調査レポート[医薬品受託製造開発機関(CDMO)アウトソーシングの世界市場予測・分析2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆